Get the Stockscreener App
9.888
0.32%
-0.032
Exozymes Inc stock is traded at $9.888, with a volume of 1,198.
It is down -0.32% in the last 24 hours and up +13.14% over the past month.
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
See More
Previous Close:
$9.92
Open:
$9.945
24h Volume:
1,198
Relative Volume:
0.28
Market Cap:
$83.74M
Revenue:
$70,100
Net Income/Loss:
$-9.16M
P/E Ratio:
-9.0491
EPS:
-1.0927
Net Cash Flow:
$-6.67M
1W Performance:
-4.23%
1M Performance:
+13.14%
6M Performance:
-26.76%
1Y Performance:
-8.87%
1-Day Range:
$9.80
$9.945
1-Week Range:
$9.66
$10.50
52-Week Range:
$7.08
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Name
Exozymes Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
9.888 | 83.74M | 70,100 | -9.16M | -6.67M | -1.0927 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exozymes Inc Stock (EXOZ) Latest News
Video Interview: Successful Pilot-Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability - The National Law Review
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Dr - The National Law Review
eXoZymes (NASDAQ:EXOZ) Shares Down 0.4%Should You Sell? - MarketBeat
Damien Alan Perriman Net Worth (2026) - GuruFocus
EXOZ Technical Analysis | Trend, Signals & Chart Patterns | EXOZYMES INC (NASDAQ:EXOZ) - ChartMill
eXoZymes Advances Toward Planned Securities Offering Preparation - The Globe and Mail
Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (E - GuruFocus
eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast By Investing.com - Investing.com Australia
Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast - Investing.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire
Why eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan
Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Exozymes Incannounces common stock offeringSEC filing - marketscreener.com
eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan
Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
EXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan
Insider Trends: Can eXoZymes Inc sustain earnings growthMarket Sentiment Review & Growth Oriented Trading Recommendations - baoquankhu1.vn
Latest EXOZ ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
EXOZ Technical Analysis & ETF Price Forecast - Intellectia AI
EXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant - Stock Titan
EXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant - Stock Titan
[Form 4] EXOZYMES INC. Insider Trading Activity - Stock Titan
Exozymes (EXOZ) CSO receives 5,332-share stock award - Stock Titan
Bond Watch: Is eXoZymes Inc a speculative investment2026 Price Swings & Detailed Earnings Play Strategies - baoquankhu1.vn
Does eXoZymes Inc stock have upside surprise potential2026 Fundamental Recap & Weekly Market Pulse Updates - baoquankhu1.vn
EXOZ PE Ratio & Valuation, Is EXOZ Overvalued - Intellectia AI
Nasdaq Moves: Is eXoZymes Inc forming a bullish divergenceShare Buyback & High Accuracy Buy Signal Tips - baoquankhu1.vn
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Bitget
EXOZ: NCT achieved kilo-scale production and tech transfer, with a financing round in progress - TradingView — Track All Markets
eXoZymes Inc's Capital Raise Delays and NCT Timeline Shifts Highlight Strategic Contradictions - Bitget
eXoZymes Q4 Earnings Call Highlights - MarketBeat
EXOZ: Pilot-scale NCT production achieved; financing round underway to support 2027 commercial launch - TradingView
Earnings call transcript: eXoZymes Q4 2025 results show strategic focus - Investing.com
eXoZymes ends 2025 with $3.04M cash as financing round nears - Stock Titan
eXoZymes Updates Investor Presentation for NCTx Business - TipRanks
eXoZymes (NASDAQ: EXOZ) files updated NCTx investor presentation - Stock Titan
eXoZymes Q4 2025 Earnings Call Transcript - MarketBeat
eXoZymes (NASDAQ: EXOZ) outlines exozyme platform and NCT plans - Stock Titan
EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Institution Moves: Can eXoZymes Inc sustain earnings growth2026 Geopolitical Influence & Technical Pattern Recognition Alerts - baoquankhu1.vn
Why Use Living Cells? NLR Is Making Chemicals With Enzymes Alone - nlr.gov
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - ACCESS Newswire
EXOZ Price Today: eXoZymes Inc. Stock Price, Quote & Chart - MEXC Exchange
Whale Trades: Can eXoZymes Inc sustain earnings growthRate Hike & High Accuracy Investment Entry Signals - baoquankhu1.vn
eXoZymes (NASDAQ:EXOZ) Shares Up 2.4%What's Next? - MarketBeat
Momentum Shift: Is eXoZymes Inc forming a bullish divergenceForecast Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
Exozymes Inc Stock (EXOZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):